A Phase 4 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 79 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one has the largest enrollment, is one of 3 that started in 2015, is one of 13 in phase 4, and was the 30th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,106 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 4, and was the 20th registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.
The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine.
The study will enroll approximately 1100 participants. All participants will receive vortioxetine 10 mg open-label for the first 16 weeks of the study. Participants who meet the appropriate MDD response criteria from the Week 8 Visit through Week 16 Visit will be eligible for randomization into the double-blind treatment period. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one capsule at the same time each day throughout the study.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 weeks. Participants will make 19 visits to the clinic, and will be contacted by telephone 4 weeks after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has one or more of the following:
Has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.
Note: For the purposes of this protocol fibromyalgia, obstructive sleep apnea, chronic pain diagnosis, and morbid obesity ( of > 40) are considered unstable due to the potential impact on assessment of the primary endpoint.
Has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
Drug: Vortioxetine
Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
Drug: Placebo
Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
Drug: Vortioxetine
Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
Drug: Vortioxetine
Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
Drug: Vortioxetine
Vortioxetine capsules
Also known as: LuAA21004
Vortioxetine placebo-matching capsules
Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile.
Time frame: From date of double-blind randomization (Week 16) up to relapse or first 28 weeks of Double-blind Period which occurs first (Up to Week 44)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses.
Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses.
Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score
The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Time frame: Week 32
Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile.
Time frame: From date of double-blind randomization (Week 16) up to relapse or 32 weeks of Double-blind Period which occurs first (Up to Week 44)
Participants took part in the study at 74 investigative sites in the United States from 10 February 2015 to 25 April 2019.
| Milestone | Open-label: Vortioxetine 10 mg | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|---|
| Started | 1106 | 0 | 0 | 0 | 0 |
| Completed | 580 | 0 | 0 | 0 | 0 |
| Not completed | 526 | 0 | 0 | 0 | 0 |
| Withdrew: Pretreatment event/adverse event | 63 | 0 | 0 | 0 | 0 |
| Withdrew: Significant protocol deviation | 19 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 55 | 0 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 91 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 116 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet randomization criteria | 162 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 9 | 0 | 0 | 0 | 0 |
| Milestone | Open-label: Vortioxetine 10 mg | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|---|
| Started | 0 | 151 | 140 | 145 | 144 |
| Completed | 0 | 70 | 84 | 96 | 86 |
| Not completed | 0 | 81 | 56 | 49 | 58 |
| Withdrew: Pretreatment event/adverse event | 0 | 4 | 3 | 2 | 9 |
| Withdrew: Significant protocol deviation | 0 | 2 | 7 | 3 | 3 |
| Withdrew: Noncompliance with study drug | 0 | 1 | 2 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 8 | 8 | 6 | 5 |
| Withdrew: Voluntary withdrawal | 0 | 12 | 8 | 9 | 11 |
| Withdrew: Relapse | 0 | 50 | 25 | 25 | 26 |
| Withdrew: Reason not specified | 0 | 3 | 3 | 2 | 1 |
| Withdrew: Missing | 0 | 1 | 0 | 0 | 0 |
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile.
| weeks | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|
| Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | NA (12 to NA) | NA (28 to NA) | NA (28 to NA) | NA (28 to NA) |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses.
| scores on scale | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|
| Change From BL II at Week 2 | 2.70 ± 0.461 | 2.23 ± 0.490 | 1.47 ± 0.471 | 2.29 ± 0.481 |
| Change From BL II at Week 4 | 4.99 ± 0.576 | 2.56 ± 0.599 | 1.98 ± 0.581 | 2.48 ± 0.602 |
| Change From BL II at Week 8 | 5.98 ± 0.688 | 3.03 ± 0.698 | 2.14 ± 0.679 | 2.97 ± 0.708 |
| Change From BL II at Week 12 | 6.43 ± 0.704 | 3.51 ± 0.701 | 1.92 ± 0.684 | 2.79 ± 0.707 |
| Change From BL II at Week 16 | 5.77 ± 0.724 | 3.73 ± 0.707 | 2.08 ± 0.688 | 3.14 ± 0.712 |
| Change From BL II at Week 20 | 5.95 ± 0.699 | 3.34 ± 0.673 | 1.86 ± 0.653 | 3.18 ± 0.675 |
| Change From BL II at Week 24 | 5.69 ± 0.765 | 3.78 ± 0.733 | 2.19 ± 0.707 | 3.16 ± 0.730 |
| Change From BL II at Week 28 | 5.07 ± 0.774 | 3.18 ± 0.730 | 2.72 ± 0.699 | 3.20 ± 0.726 |
| Change From BL II at Week 32 | 6.55 ± 0.858 | 3.46 ± 0.815 | 2.58 ± 0.784 | 2.97 ± 0.815 |
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses.
| scores on scale | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|
| Change From BL II at Week 2 | 0.35 ± 0.065 | 0.32 ± 0.069 | 0.26 ± 0.067 | 0.27 ± 0.068 |
| Change From BL II at Week 4 | 0.61 ± 0.075 | 0.32 ± 0.078 | 0.30 ± 0.076 | 0.25 ± 0.078 |
| Change From BL II at Week 8 | 0.68 ± 0.091 | 0.38 ± 0.092 | 0.29 ± 0.089 | 0.30 ± 0.093 |
| Change From BL II at Week 12 | 0.74 ± 0.092 | 0.46 ± 0.091 | 0.24 ± 0.089 | 0.35 ± 0.092 |
| Change From BL II at Week 16 | 0.62 ± 0.094 | 0.50 ± 0.091 | 0.25 ± 0.088 | 0.34 ± 0.091 |
| Change From BL II at Week 20 | 0.61 ± 0.094 | 0.40 ± 0.089 | 0.17 ± 0.086 | 0.28 ± 0.089 |
| Change From BL II at Week 24 | 0.60 ± 0.103 | 0.45 ± 0.098 | 0.24 ± 0.094 | 0.37 ± 0.097 |
| Change From BL II at Week 28 | 0.45 ± 0.101 | 0.33 ± 0.094 | 0.30 ± 0.090 | 0.34 ± 0.093 |
| Change From BL II at Week 32 | 0.59 ± 0.108 | 0.41 ± 0.101 | 0.26 ± 0.097 | 0.22 ± 0.100 |
The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
| scores on scale | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|
| Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | 4.4 ± 1.47 | 3.9 ± 1.51 | 3.5 ± 1.72 | 3.7 ± 1.56 |
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile.
| weeks | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|
| Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | NA (12 to NA) | NA (32 to NA) | NA (32 to NA) | NA (32 to NA) |
Collected over From first dose of study drug and up to 30 days after the last dose (Up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label: Vortioxetine 10 mg | 0/1,106 (0%) | 9/1,106 (0.8%) | 417/1,106 (37.7%) |
| Double-blind: Placebo | 0/151 (0%) | 1/151 (0.7%) | 16/151 (10.6%) |
| Double-blind: Vortioxetine 5 mg | 0/140 (0%) | 3/140 (2.1%) | 30/140 (21.4%) |
| Double-blind: Vortioxetine 10 mg | 1/145 (0.7%) | 4/145 (2.8%) | 27/145 (18.6%) |
| Double-blind: Vortioxetine 20 mg | 0/144 (0%) | 0/144 (0%) | 32/144 (22.2%) |
| Event | Open-label: Vortioxetine 10 mg | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|---|
| VertigoEar and labyrinth disorders | 0/1106 | 0/151 | 1/140 | 0/145 | 0/144 |
| Ankle fractureInjury, poisoning and procedural complications | 0/1106 | 0/151 | 1/140 | 0/145 | 0/144 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1106 | 0/151 | 1/140 | 0/145 | 0/144 |
| Post procedural cellulitisInfections and infestations | 0/1106 | 0/151 | 0/140 | 1/145 | 0/144 |
| PyelonephritisInfections and infestations | 0/1106 | 0/151 | 0/140 | 1/145 | 0/144 |
| Completed suicidePsychiatric disorders | 0/1106 | 0/151 | 0/140 | 1/145 | 0/144 |
| NephrolithiasisRenal and urinary disorders | 0/1106 | 0/151 | 0/140 | 1/145 | 0/144 |
| Cardiac failureCardiac disorders | 0/1106 | 1/151 | 0/140 | 0/145 | 0/144 |
| Suicidal ideationPsychiatric disorders | 2/1106 | 0/151 | 0/140 | 0/145 | 0/144 |
| Abdominal pain upperGastrointestinal disorders | 1/1106 | 0/151 | 0/140 | 0/145 | 0/144 |
| Event | Open-label: Vortioxetine 10 mg | Double-blind: Placebo | Double-blind: Vortioxetine 5 mg | Double-blind: Vortioxetine 10 mg | Double-blind: Vortioxetine 20 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 292/1106 | 2/151 | 4/140 | 5/145 | 13/144 |
| HeadacheNervous system disorders | 91/1106 | 0/151 | 0/140 | 0/145 | 0/144 |
| Upper respiratory tract infectionInfections and infestations | 0/1106 | 6/151 | 9/140 | 9/145 | 9/144 |
| Back painMusculoskeletal and connective tissue disorders | 0/1106 | 2/151 | 8/140 | 0/145 | 2/144 |
| NasopharyngitisInfections and infestations | 56/1106 | 4/151 | 7/140 | 7/145 | 8/144 |
| Weight increasedInvestigations | 0/1106 | 3/151 | 5/140 | 7/145 | 8/144 |
| Dry mouthGastrointestinal disorders | 58/1106 | 0/151 | 0/140 | 0/145 | 0/144 |
Safety Set for Open-label Period included all participant who received at least 1 dose of Open-label study medication. Baseline I is defined as the last non-missing observation prior to the first dose of open-label study drug.
| Age, Continuous(years) | Open-label: Vortioxetine 10 mg |
|---|---|
| Mean | 44.3 ± 13.69 |
| Sex: Female, Male(Participants) | Open-label: Vortioxetine 10 mg |
|---|---|
| Female | 807 |
| Male | 299 |
| Ethnicity (NIH/OMB)(Participants) | Open-label: Vortioxetine 10 mg |
|---|---|
| Hispanic or Latino | 145 |
| Not Hispanic or Latino | 961 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Open-label: Vortioxetine 10 mg |
|---|---|
| American Indian or Alaska Native | 7 |
| Asian | 19 |
| Native Hawaiian or Other Pacific Islander | 10 |
| Black or African American | 258 |
| White | 790 |
| More than one race | 19 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(Participants) | Open-label: Vortioxetine 10 mg |
|---|---|
| United States | 1106 |
| Height(cm) | Open-label: Vortioxetine 10 mg |
|---|---|
| Mean | 167.7 ± 9.38 |
| Weight(kg) | Open-label: Vortioxetine 10 mg |
|---|---|
| Mean | 82.92 ± 18.695 |
| Body Mass Index (BMI)(kg/m^2) | Open-label: Vortioxetine 10 mg |
|---|---|
| Mean | 29.39 ± 5.731 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2015 to primary completion in Mar 2019, 48 months.
Results were first posted in Apr 2020, 1 year 1 month after primary completion.
Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 48 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine